Title
Discover hidden splicing variations by mapping personal transcriptomes to personal genomes.

Permalink
https://escholarship.org/uc/item/8x6058m6

Journal
Nucleic acids research, 43(22)

ISSN
1362-4962

Authors
Stein, Shayna
Lu, Zhi-Xiang
Bahrami-Samani, Emad
et al.

Publication Date
2015-12-01

DOI
10.1093/nar/gkv1099

Peer reviewed
Discover hidden splicing variations by mapping personal transcriptomes to personal genomes

Shayna Stein†, Zhi-xiang Lu†, Emad Bahrami-Samani, Juw Won Park and Yi Xing∗

Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA

Received August 27, 2015; Revised October 07, 2015; Accepted October 09, 2015

ABSTRACT

RNA-seq has become a popular technology for studying genetic variation of pre-mRNA alternative splicing. Commonly used RNA-seq aligners rely on the consensus splice site dinucleotide motifs to map reads across splice junctions. Consequently, genomic variants that create novel splice site dinucleotides may produce splice junction RNA-seq reads that cannot be mapped to the reference genome. We developed and evaluated an approach to identify ‘hidden’ splicing variations in personal transcriptomes, by mapping personal RNA-seq data to personal genomes. Computational analysis and experimental validation indicate that this approach identifies personal specific splice junctions at a low false positive rate. Applying this approach to an RNA-seq data set of 75 individuals, we identified 506 personal specific splice junctions, among which 437 were novel splice junctions not documented in current human transcript annotations. 94 splice junctions had splice site SNPs associated with GWAS signals of human traits and diseases. These involve genes whose splicing variations have been implicated in diseases (such as OAS1), as well as novel associations between alternative splicing and diseases (such as ICA1). Collectively, our work demonstrates that the personal genome approach to RNA-seq read alignment enables the discovery of a large but previously unknown catalog of splicing variations in human populations.

INTRODUCTION

Exons can be differentially included in the mature mRNA products during splicing (1). This process, called alternative splicing (AS), is one of the predominant mechanisms for generating distinct mRNA isoforms from a single gene. It is estimated that over 90% of human multi-exon genes are alternatively spliced (2,3). AS plays a crucial role in gene regulation and abnormal variations in splicing can have significant disease consequences (4). In fact, as high as 50% of disease-causing mutations in specific disease genes may alter splicing (5,6).

In recent years, numerous studies have identified single nucleotide polymorphisms (SNPs) that are associated with changes in nearby AS events, commonly referred to as splicing quantitative trait loci (sQTLs) (7–10). Collectively, these studies have established that natural genetic polymorphisms in the human population may cause differences in exon usage patterns or splicing efficiencies among individuals. Such natural variation of alternative splicing may in turn influence disease risk or severity or therapeutic response (11–13). Thus, the discovery of sQTLs will reveal potential mechanisms underlying human phenotypic diversity and susceptibility to genetic disorders.

AS is regulated by a wide array of cis regulatory elements on the pre-mRNA as well as trans-acting factors that interact with these cis elements (14). The most conserved cis splicing signals within the pre-mRNA are the 5′ and 3′ splice sites, which define the boundary between exons and introns. Approximately 99% of mammalian splice sites follow the ‘GT-AG’ dinucleotide rule such that the first two and last two nucleotides in the intron are GT and AG, respectively. Of the remaining splice sites, ≈0.9% are ‘GC-AG’ and ≈0.09% are ‘AT-AC’ (15). Genetic variants that disrupt or create the highly conserved splice site dinucleotide motifs can alter splicing patterns and produce alternative mRNA and protein isoforms (16). Indeed, mutations that affect splice site dinucleotides represent a large class of human disease mutations (17).

RNA sequencing (RNA-seq) has emerged as a powerful method for discovering and quantifying AS events at the whole-transcriptome scale. In a typical RNA-seq data analysis workflow, sequenced fragments of mRNA (i.e. reads) are aligned to the reference genome sequence and/or existing transcript annotations, and reads corresponding to specific exons and splice junctions are identified and counted to generate quantitative estimates of gene expression and alternative splicing (18–21). A number of studies have used
this strategy to identify associations between genetic polymorphisms and alternative splicing events in human populations (22–28). However, the use of the reference genome has important limitations for studying individual variations of transcriptomes. For example, it is well known that when mapping reads to the reference genome, exonic SNPs can create a bias for mapping RNA-seq reads harboring the reference alleles over reads harboring the derived alleles, which may skew the quantitation of allelic ratios in RNA-seq data and confound downstream analyses of allele-specific gene expression and RNA processing (29). Methods have been developed to alleviate such biases in mapping personal RNA-seq data (30–32). Another major limitation, which is the main motivation for this work, is the identification of splice junctions from personal RNA-seq reads aligned to the reference genome. Many commonly used RNA-seq aligners, including TopHat and SpliceMap (33,34), rely on the canonical (e.g. GT-AG, GC-AG, AT-AC) splice site dinucleotide motifs and do not align reads to non-canonical splice junctions. Other aligners, such as STAR and HISAT (35,36), apply a severe score penalty to non-canonical splice junction alignments. As a result, if a genetic polymorphism creates a novel splice site dinucleotide motif in an individual, RNA-seq reads that originate from the polymorphic splice site in the personal genome will be unlikely to be mappable to the human reference genome due to the lack of the canonical splice site dinucleotide motif in the reference genome sequence (Figure 1A). This would result in ‘hidden’ splicing variations that are undetected by standard RNA-seq alignment procedures.

In this work, we explored whether a personal genome approach to RNA-seq alignment could detect such hidden splicing variations. In a collection of RNA-seq data of 75 European individuals from the 1000 Genomes Project, we identified 506 ‘hidden’ personal splice junctions with polymorphic splice site dinucleotides that were supported by RNA-seq reads unmappable to the human reference genome. 437 of these splice junctions were novel, i.e. not in current human transcript annotations, and 94 were linked to genome-wide association study (GWAS) signals. Our data demonstrate that by mapping personal RNA-seq data to personal genomes, we can uncover numerous novel splicing variations in the human population, including those potentially underlying GWAS signals of complex human traits and diseases. We refer to our pipeline RNA-seq Personal Genome-alignment Analyzer (rPGA). The rPGA source code and user documents are freely available for download at https://github.com/Xinglab/rPGA.

MATERIALS AND METHODS

RNA-seq data sets

RNA-seq data for NA12891 were obtained from the NCBI Sequence Read Archive (SRR074943) (24). RNA-seq data for 75 European individuals were obtained from the Gvadis RNA Sequencing Project (Supplementary Table S1; EBI ArrayExpress: E-GEUV-1) (25). All RNA-seq data were generated on lymphoblastoid cell lines (LCLs). Genotype data for these individuals were taken from the 1000 Genomes Browser (37). The genotype data were filtered to only include phased SNPs.

RNA-seq read alignment

For each individual, the paired-end RNA-seq reads were aligned to hg19 and two haplotype versions (hap1 and hap2) of the personal genome using STAR (version 2.4.0f1) (35), generating three separate sets of alignment data. The maximum number of mismatches within reads was set to 0, the maximum number of multihits was set to 20 and the maximum intron size was set to 300 000. The minimum overhang length for splice junctions was set to 12 for GT/AG, GC/AG and AT/AC splice site dinucleotide motifs. Spliced alignments containing non-canonical splice junctions were not permitted. Truncated reads and reads with a truncated pair were considered unmapped.

Identification of personal specific splice junctions

Hap1 specific junctions were splice junctions reported solely in the hap1 alignment data. Similarly, hap2 specific junctions were splice junctions reported solely in the hap2 alignment data and hap1/hap2 specific junctions were splice junctions found in both the hap1 and hap2 alignment data but not in the hg19 alignment data. Personal specific splice junctions were defined to be the union of hap1, hap2 and hap1/hap2 specific splice junctions. Likewise, splice junctions reported solely in the hg19 alignment data were called hg19 specific junctions, which can be used to assess the false positive rate of our procedure. Distinct reads were ones that had distinct starting alignment positions. We required personal specific splice junctions to be supported by ≥2 distinct reads for all further analyses.

Splice site usage frequency

To compare the relative splicing activities at a personal specific splice site to nearby alternative splice sites, we calculated the splice site usage frequency using RNA-seq data. Note that frequencies were calculated only in the genome where the splice junction was identified. For example, a personal specific splice junction identified in one haplotype was only compared to all other junctions also found in that haplotype.

To calculate the relative usage frequency of personal splice junctions, we considered all Ensembl annotated splice junctions with overlapping genomic coordinates with our personal splice junction of interest. PSJ is the number of reads that span the personal specific splice junction and OSJ is the total number of reads that span all overlapping Ensembl annotated junctions. The relative usage frequency of the personal splice junction is PSJ/(PSJ + OSJ). We also performed this calculation for a subset of personal specific splice junctions that overlapped with only one other splice junction via alternative 5′ or 3′ splice site patterns. The number of reads supporting a splice junction was counted as the number of distinct splice junction spanning reads, i.e. reads with distinct genomic starting alignment positions.

Association with GWAS signals

We obtained 207 889 GWAS SNPs with P-value < 10^{-3} from the GWASdb2 v4 catalog (38). We used PLINK
Linkage disequilibrium (LD) plot

Linkage disequilibrium (LD) plot for SNP rs6948664 was generated using Haploview v4.2 (40). CEU LD data were obtained from the HapMap Project Genome Browser version E, using data release #28 (Phase II+III).

Splice site score

Splice site (SS) scores (5' or 3' splice sites) were calculated using the MaxEntScan maximum entropy model (41). In cases where the personal SNP also affected the reference splice site, reference splice site sequences were changed accordingly to reflect the personal SNP. We defined \( \Delta(\text{SS score}) = \text{personal splice site score} - \text{reference splice site score} \), where \( \Delta(\text{SS score}) > 0 \) corresponds to a personal splice site that is stronger than the alternative reference splice site.

Experimental validation of personal specific splice junctions

HapMap LCLs were purchased from the Coriell Institute for Medical Research (Camden, NJ, USA). We prepared HapMap LCLs’ cDNAs as described before (42). To validate personal specific splice junctions, we designed a pair of polymerase chain reaction (PCR) primers targeting flanking constitutive exons of the novel splice junction. Regular PCR was carried out for 40 cycles. Final PCR products were purified by gel extraction and then confirmed by Sanger sequencing (Laragen, Inc, CA, USA). Primer sequences and HapMap individuals selected for PCR validation are shown in Supplementary Table S2.

RESULTS

A computational pipeline to identify personal splice junctions by mapping personal RNA-seq data to personal genomes

We developed a computational pipeline rPGA (Figure 1B) to discover hidden splice junctions by mapping personal RNA-seq data to the matching personal genome sequence. We applied this pipeline to analyze RNA-seq data from individuals with whole-genome genotype data in the 1000 Genomes project. Briefly, for each individual we modified the human reference genome (hg19) according to its genotype, resulting in two versions of personal genome sequences per individual (one for each haplotype), which we referred to as haplotype 1 (hap1) and haplotype 2 (hap2) in this manuscript. Next, an individual’s RNA-seq reads were aligned to the human reference genome (hg19) and each of the two corresponding personal genomes (hap1 and hap2) using the RNA-seq alignment software STAR (35), resulting in three separate sets of alignment data per individual. We should note that STAR truncates a read once it reaches the maximum number of allowed mismatches or has too low of an alignment score (35). We considered such truncated reads as well as reads that did not align at all unmappable reads. We then remapped reads that were unmappable to hg19 to personal genomes (hap1 and hap2) to identify personal specific splice junctions (Figure 1). To constrain our analysis to the effect of splice site SNPs, we filtered out personal specific splice junctions with no SNP at the splice site dinucleotide motifs. 99.2% of filtered per-
Personal specific splice junctions were supported by reads that could have been aligned to the same location in the hg19 reference genome, but contained SNP(s) elsewhere along the reads that made them unmappable to hg19 due to the number of mismatches exceeding the aligner’s threshold. To assess the rate of false positives from this pipeline, we reversed the alignment procedure by re-aligning reads unmappable to personal genomes (hap1 and hap2) to hg19 to identify hg19-specific splice junctions. We consider such hg19-specific splice junctions false positives, because their supporting splice junction reads were generated from the personal genome sequence of the individual.

As a proof-of-concept analysis using this pipeline, we initially performed personal genome RNA-seq alignment using RNA-seq data of a male Caucasian (NA12891) (24). We identified 33 personal specific splice junctions, including 24 novel splice junctions not documented in current human transcript annotations (Ensembl version #75). The reverse mapping procedure (see above) identified only 3 hg19-specific splice junctions, suggesting that our pipeline has low false positives. We also checked whether our pipeline could identify known alternative splicing variations arising from personal specific splice junctions. Indeed, we successfully captured a known personal specific 3′ splice site of intron 20 in NPHP4 associated with SNP rs1287637 (T > A) on the RNA sense strand which created an ‘AG’ 3′ splice site. NPHP4 is involved in renal function and its mutations are known to cause juvenile end stage renal disease (43). The personal splice junction is supported by 5 distinct reads, though it is unlikely to be identified through traditional reference genome based RNA-seq mapping because the supporting reads are unmappable to hg19 due to the lack of canonical splice site dinucleotides in the reference genome. Interestingly, the T allele in the reference genome causes activation of two downstream 3′ splice sites and is associated with alternative transcript isoforms with 6 nt and 42 nt deletions of exon 21. Individuals carrying the ‘T’ allele of SNP rs1287637 (i.e. A/T or T/T genotype) have reduced renal function manifested as decreased glomerular filtration rate (43). This example shows that our strategy can identify personal specific splice junctions that would otherwise be missed when mapping RNA-seq reads to the reference human genome.

**Comprehensive identification of personal specific splice junctions in 75 European individuals**

Next, we expanded our analysis to RNA-seq data of 75 European individuals. These data were obtained from the Geuvadis RNA sequencing project on 1000 Genomes samples (23) (see Materials and Methods). We identified a total of 506 distinct personal specific splice junctions among the 75 individuals (Figure 2A and Supplementary Table S3), with at least two distinct supporting RNA-seq reads in at least one individual. The reverse alignment procedure identified only 27 hg19-specific splice junctions. In fact, at the same threshold of supporting evidence, the number of hg19-specific splice junctions was always at most a few percent of the number of personal specific splice junctions (see Supplementary Figure S1), suggesting that the false positive rate of our pipeline was consistently low even for splice junctions identified in only a single individual. We also compared our results to the Ensembl transcript annotations (version #75) (44) to classify personal specific splice junctions as either known or novel. The 506 splice junctions included 69 known and 437 novel splice junctions (Figure 2B). Our list of 69 known personal specific splice junctions includes events with documented disease relevance. For example, a known personal specific splice junction in IRF5 was identified in 25 individuals. Splice site SNP rs2004640 (G > T on the RNA sense strand) creates an alternative ‘GT’ 5′ splice site to enable the splicing of exon 1B as an alternative first exon (45). Interestingly, IRF5 has four alternative first exons, all of which are in the 5′-UTR (46). Exon 1B is the only alternative first exon with a p53-binding site in the associated promoter region (47). Furthermore, the T allele of rs2004640 has 2.7-fold higher IRF5 mRNA level (46). Overexpression of IRF5 is associated with susceptibility of autoimmune diseases, including systemic lupus erythematos, rheumatoid arthritis and multiple sclerosis (48,49). A second example is a known splice junction in CPNE1 identified in 9 individuals. An exonic SNP rs2425068 (A > G) immediately downstream of the canonical 3′ splice site creates a pair of tandem NAGNAG 3′ splice sites (CAGCAA > CAGCAG) (50). Use of the downstream 3′ splice site results in one amino acid 413Q deletion in the VWFA (Von Willebrand Factor Type A) domain. This SNP is associated with plasma protein C levels and potentially venous thromboembolism (51).

We next asked whether these ‘hidden’ personal splice junctions could be expressed at a high enough level to be considered more than just baseline splicing noise. For this analysis, we calculated the relative usage frequency of the identified personal splice junctions using RNA-seq data (see Materials and Methods). As expected, personal splice junctions had a wide range of usage frequencies. 460, 311 and 193 of the 506 personal splice junctions had an average usage frequency no less than 5%, 15% and 50%, respectively, when detected. For example, SNP rs2004640 (G > T) in IRF5 as mentioned above had average personal splice junction usage frequency of ≈11% in 25 individuals, while SNP rs2425068 (A > G) in CPNE1 had average personal splice junction usage frequency of ≈65% in 9 individuals. We also calculated the detection frequency of personal splice junctions across individuals, as the percentage of individuals with a given personal splice junction detected among all individuals carrying the splice site SNP. We found that 323, 218 and 108 personal splice junctions had a detection frequency no less than 5%, 15% and 50%, respectively, among individuals carrying the splice site SNPs. These results indicate that personal specific splice junctions arising from splice site polymorphisms can be used in a significant portion of the final transcript products within the population.

We performed an in-depth analysis to assess how the usage frequency of personal specific splice junctions was correlated with the strength of their associated splice sites. To remove potential confounding factors and obtain meaningful estimates of splice junction usage frequencies, we imposed several additional requirements: first, the personal specific splice junction must form alternative 5′ or 3′ splice sites with exactly one other reference splice junction expressed in the personal transcriptome; second, the personal
Figure 2. Number of personal specific splice junctions supported by different numbers of RNA-seq reads and individuals. Heatmap of (A) the total number of personal specific splice junctions, and (B) the total number of novel personal specific splice junction identified across 75 CEU individuals. Columns represent an increasing requirement for the minimum number of supporting splice junction reads. Rows represent an increasing requirement for the minimum number of supporting individuals.

and reference splice junctions must have a minimum combined read count of 10 distinct RNA-seq reads to ensure a high enough coverage for estimating splice junction usage frequencies; and third, individuals must be homozygous for the splice site SNP because relative splice junction frequency in the RNA-seq data is dependent on the genotype of the individual. We identified a total of 149 instances of personal specific splice junctions that met these criteria. Among them, 77 had weaker splice sites compared to the reference splice sites, and 72 had stronger splice sites compared to the reference splice sites. We found that personal splice junctions with stronger splice sites had significantly higher usage frequencies than those with weaker splice sites (mean frequency 36.2% versus 19.7%; \( P = 5.5 \times 10^{-4} \), Wilcoxon test) (Supplementary Figure S2).

Experimental validation of personal specific splice junctions

We used PCR followed by Sanger sequencing to perform experimental validation of novel personal specific splice junctions. PCR analyses were carried out in lymphoblastoid cell lines (LCLs) carrying the personal specific splice junctions of interest. To facilitate PCR primer design and analysis, we randomly selected eight novel personal specific splice junctions which had alternative 5' or 3' splice site patterns with at least one other annotated splice site and a usage frequency of at least 10% in the corresponding individuals. A pair of PCR primers targeting flanking constitutive exons was designed for each novel personal specific splice junction. Putative PCR amplicons were further confirmed by Sanger sequencing. All eight novel splice junctions were validated (Table 1). We validated novel personal specific splice junctions present in as few as 1 individual and as many as 69 individuals.

One example of validated splice junctions is a personal splice junction of exon 6 of OAS1, observed in RNA-seq data of 69 individuals. OAS1 encodes 2'-5'-oligoadenylate synthetase and is involved in viral and endogenous RNA degradation to inhibit viral replication (52). Splice site SNP rs10774671 (G > A) creates a cryptic 3' splice site that is shifted 1 nt downstream from the canonical 3' splice site in the reference genome. Simultaneously, rs10774671 corrupts the reference 3' splice site (AG > AA) as shown in Figure 3A. Usage of the personal splice junction is predicted to produce a protein isoform (i.e. p52) with reduced enzyme activity and can thus affect immune response to viral infection (53).

A second example is a novel personal specific splice junction in exon 8 of DHRS12 that was identified in one individual (Figure 3B). DHRS12 codes for an enzyme in the short-chain dehydrogenases/reductases (SDR) family. Although DHRS12 itself is not a well-characterized gene, it is known that SDRs in general are responsible for metabolizing substances in the body including hormones and xenobiotics (54–56). Mutations in these genes have been associated with a variety of metabolic disorders (57). Splice site SNP rs2296028 (C > G on the RNA sense strand) creates a stronger, novel 3' splice site (splice site score = 9.61 by MAXENT (41)) 5 nt upstream from the reference 3' splice site (score = 4.11) (Figure 3B). Moreover, the G allele of SNP rs2296028 decreases the reference 3' splice site score from 4.11 to 0.25. RNA-seq data as well as our PCR and sequencing data indicate that this much stronger novel 3' splice site is used in one individual heterozygous for the splice site SNP.

We should note that these eight validated splice junctions were randomly selected from our identified novel personal specific splice junctions, rather than being cherry-picked from the most frequently expressed and identified novel splice junctions. Our independent experimental validation confirmed the existence of hidden personal splicing variations that would otherwise be overlooked by mapping personal RNA-seq reads to the reference genome.
Table 1. Experimental validation of novel personal specific splice junctions

| Gene symbol | Genomic coordinates (hg19) | Average relative usage frequency | Frequency standard deviation | # Individuals supported | GWAS disease/trait | Validated novel |
|-------------|--------------------------|---------------------------------|-----------------------------|------------------------|--------------------|-----------------|
| ANXA6       | chr5:150483256–150484805 | 0.48                            | 0                           | 1                      | Yes                | Yes             |
| ARSG        | chr17:66352945–66364691  | 0.82                            | 0.18                        | 15                     | Yes                | Yes             |
| ASMYL       | chrX:1540735–1544272     | 0.10                            | 0                           | 1                      | Yes                | Yes             |
| DHRS12      | chr11:52445636–5245956   | 0.23                            | 0                           | 1                      | Coronary Artery Disease (72) | Yes | Yes |
| GRAMD1A     | chr19:35505291–35506730  | 0.65                            | 0.08                        | 43                     | Yes                | Yes             |
| NPNT        | chr4:10681680–106839654  | 0.65                            | 0.28                        | 9                      | Yes                | Yes             |
| OAS1        | chr12:111355050–111357194 | 0.21                            | 0.07                        | 69                     | Multiple complex diseases (73) | Yes | Yes |
| U2AF1L4     | chr19:36233704–36234652  | 0.28                            | 0.09                        | 6                      | Yes                | Yes             |

Figure 3. Experimental validation and sequencing chromatograms of personal specific splice junctions in OAS1 and DHRS12. (A) SNP rs10774671 creates a personal 3′ splice site of OAS1. The reference 3′ splice site produces an intact protein isoform p46. The SNP rs10774671 (G to A) abolishes the reference 3′ splice site, resulting in the usage of a personal 3′ splice site and an internal cryptic 3′ splice site corresponding to alternative protein isoforms p52 and p48 with reduced enzyme activity. (B) SNP rs2296028 creates a personal 3′ splice site 5 nt upstream of the reference 3′ splice site of DHRS12 exon 8. This SNP also decreases the score of the reference 3′ splice site from 4.11 to 0.25. 3′ SS: 3′ splice site.
Personal specific splice junctions are linked to GWAS signals of complex traits and diseases

Finally, we investigated whether our discovered personal specific splice junctions were associated with GWAS signals of complex traits and diseases. GWAS studies have identified an abundance of associations between genomic variants and phenotypes. Interpreting the growing catalog of GWAS signals is a powerful application for elucidating human transcriptome variation (23). However, more often than not, GWAS signals merely serve as markers for phenotype association and reveal little regarding the underlying causal genomic variants as well as the molecular mechanisms for phenotype variability or disease pathogenesis (58). Although initial analyses of GWAS signals focused on those in protein coding regions, recent evidence suggests that many functional variants lie in non-coding regions and affect phenotypes through regulatory mechanisms (59). As alternative splicing plays a powerful role in transcriptome variation and phenotype diversity (13), personal specific splice junctions arising from splice site SNPs are likely candidates for functional causal variants associated with GWAS signals. To investigate this, we sought to identify all personal splice junction associated splice site SNPs in high $r^2 > 0.8$ LD with GWAS signals listed in GWASdb v4 (see Materials and Methods) (38). GWASdb integrates a number of well-established collections of GWAS SNPs, including the commonly used NHGRI GWAS catalog (60). We identified 9 known and 85 novel personal specific splice junctions with splice site SNPs linked to GWAS signals (Supplementary Table S4 and Table 2). The list includes our experimentally validated splice junctions in OAS1 and DHR12 (described above), as well as other personal splice junction associated SNPs with potential medical significance.

A highly intriguing example is a personal specific splice junction in ICA1. ICA1 encodes autoantigen ICA69, which is involved in vehicular transport of insulin secretory granule proteins and is known to play an important role in autoimmune diseases, including type 1 diabetes, rheumatoid arthritis and Sjogren’s syndrome (61–64). SNP rs6948664 ($C > T$) activates a novel 5′ splice site ($GC > GT$; 5′ splice site score = 8.4) in intron 12 of ICA1. Our RNA-seq alignment indicates that this novel 5′ splice site is paired with the downstream 3′ splice site of exon 13. However, in the RNA-seq data we did not find any splice junction reads from exon 12 or other upstream exons into the potential novel exon within intron 12, raising the possibility that this novel personal specific splice junction may be associated with a novel alternative first exon within intron 12. To test this hypothesis, we designed a pair of PCR primers targeting exon 12 and exon 13 of ICA1, and a separate pair of PCR primers targeting the potential novel exon in intron 12 and exon 13. As expected, the novel personal specific splice junction was only observed in individuals carrying the T allele of rs6948664 (Figure 4). Moreover, the primer pair targeting the two flanking exons (exon 12 and 13) failed to amplify any PCR amplicon that contained the potential novel exon in intron 12, suggesting that the novel personal specific splice junction is not paired with an upstream splice junction that creates a novel internal exon of ICA1. Thus, we conclude that rs6948664 activates a novel alternative first exon in ICA1. Of note, the use of this novel alternative first exon is expected to produce a much shorter mRNA isoform ($≈$1100nt), compared to the full-length mRNA transcript (2473 nt, NM_001136020), and the longest putative open reading frame of the novel transcript is only 75aa. The predicted 75aa protein isoform has the same reading phase as the canonical mRNA isoform but loses the AH domain, which has been shown to dimerize and bind to Arf and Rho family GTPases (65,66). Arf and Rho GTPases are required for regulation of many cellular processes including cell motility and Golgi function (65). The novel personal specific splice junction was identified in 23 individuals, with an average usage frequency of 59%. Additionally, rs6948664 is in complete LD ($r^2 = 1$) with GWAS signal rs4725072, which has been identified as significantly associated with systemic lupus erythematosus (SLE) and systemic sclerosis (38,67). However, no underlying causal variants were identified for SLE or systemic sclerosis in the original GWAS study. Interestingly, individuals showing RNA-seq evidence for the novel personal specific splice junction have significantly higher ICA1 gene expression levels in LCL cells compared to those without ($P = 7 \times 10^{-3}$, Wilcoxon test). It has been found that overexpression of ICA1 in insulinoma INS-1 cells impairs secretory granule protein transport (61). Collectively, our data suggest that rs6948664 is a likely causal variant for SLE or systemic sclerosis by significantly affecting ICA1’s expression level and/or protein output. We note that recent work has described the roles of first exon and 5′ splice site in transcriptional regulation (68–70), which could underlie our observed association between this alternative first exon and ICA1 gene expression level. However, we cannot rule out the possibility that this observation could be due to the simple fact that it is more likely to detect such an alternative mRNA isoform by RNA-seq when the overall gene expression level is high. Further studies are needed to assess the causal impact of this novel alternative first exon on ICA1 gene transcription and function.

Of all GWAS-associated personal splice junctions, 63 formed alternative 5′ or 3′ splice sites with reference splice junctions. 40 of these 63 GWAS-associated personal splice junctions (63.5%) were potentially frame-shifting because the distance between the personal and reference splice sites was not an exact multiple of three nucleotides. The percentage was similar in non-GWAS-associated personal splice junctions.

DISCUSSION

Dissecting the molecular mechanisms of transcriptome variation in human populations is critical for understanding the biology of complex traits and diseases. Alternative splicing is a major contributor to transcriptome variation and phenotypic diversity among human individuals (9,10,13). Thus, identifying splicing variations in human populations will shed light on the genetic basis of diseases. A number of recent studies have used RNA-seq to characterize genetic variation of alternative splicing in human cell lines and tissues (22–28). These studies typically generate quantitative estimates of alternative splicing using RNA-seq reads aligned to a single reference genome. However, as
Table 2. Selected list of personal specific splice junction SNPs linked to GWAS signals

| Gene symbol | Genomic coordinates (hg19) | Novel | Splice site SNP | Linked GWAS SNP(s) | GWAS gene symbol | GWAS disease/trait | Reference |
|-------------|---------------------------|-------|----------------|-------------------|------------------|-------------------|-----------|
| AHRR        | chr5:428122–430060         | Yes   | rs72173415      | rs1218464         | AHRR             | Cystic fibrosis severity | (74)      |
| ALG8        | chr11:77838483–7750518     | Yes   | rs107931299     | rs10999440        | ALG8             | Endometriosis       | (75)      |
| ATP5A1      | chr18:43671818–43673144    | Yes   | rs8039598       | rs3397709, rs7244921, rs8099150 | ATP5A1 | HIV-1 disease progression | (76)      |
| DHRS12      | chr13:52345636–52345956    | Yes   | rs2296628       | rs2296628         | DHRS12           | Coronary artery disease | (72)      |
| ICA1        | chr7:8167773–8168380       | Yes   | rs9048664       | rs4725072         | ICA1             | Systemic lupus erythematosus and systemic sclerosis | (67)      |
| NBR2        | chr17:41290940–41291953    | Yes   | rs11657835      | rs11655505        | NBR2             | Breast Neoplasms    | (77)      |
| NDUFAF6     | chr9:5958208–59593802      | Yes   | rs1008948       | rs10093776        | NDUFAF6          | Blood pressure      | (78)      |
| OAS1        | chr11:13355506–13357914    | Yes   | rs1074071       | rs2960           | OAS1             | Multiple complex diseases | (73)      |
| PPP1R3B     | chr8:8999187–9000872       | Yes   | rs30924         | rs380911         | PPP1R3B          | Alzheimer’s disease (late onset) | (79)      |
| STYXL1      | chr7:75630274–75633075     | Yes   | rs6565          | rs6978677        | STYXL1           | Lymphocyte counts | (80)      |

Figure 4. A personal specific splice junction of ICA1 is linked to GWAS signals of diseases. (A) The schematic gene structure and sequencing chromatogram of the novel personal specific splice junction in ICA1. SNP rs6948664 creates a novel personal 5′ splice site in intron 12 of ICA1, resulting in a novel alternative first exon of ICA1. (B) Linkage disequilibrium (LD) plot of the CEU population indicates that the personal specific splice junction SNP rs6948664 is in perfect LD with the GWAS SNP of systemic lupus erythematosus and sclerosis rs4725072 ($r^2 = 1$).

we demonstrated in this work, important splicing variations may be missed by mapping personal RNA-seq reads to the reference genome.

In this study we implemented a computational pipeline rPGA (RNA-seq Personal Genome-alignment Analyzer; https://github.com/Xinglab/rPGA) to identify splicing variations in individual transcriptomes, by mapping personal RNA-seq reads to personal genomes. The importance of using personal genome information has been discussed previously for RNA-seq studies, mostly for the purpose of reducing allelic bias in mapping personal RNA-seq reads to the reference genome (30–32). Here we investigated a distinct issue in RNA-seq alignment, namely the identification of novel, personal specific splice junctions from personal RNA-seq data. Because commonly used RNA-seq aligners all rely on the consensus splice site dinucleotide motifs to map reads across splice junctions, if a genetic polymorphism creates a novel splice site dinucleotide motif, the result-
ing splice junction reads utilizing this novel splice site will likely be unmappable to the reference genome by a standard RNA-seq aligner. Indeed, using a eukaryotic genome alignment approach, we identified many novel personal specific splice junctions at a low false positive rate (Figure 2). Moreover, eight novel splice junctions selected for experimental testing were all validated by RT-PCR and sequencing. Thus, our results indicate that we could uncover ‘hidden’ splicing variations in individual transcriptomes by aligning personal RNA-seq reads to personal genomes. We should clarify that not all personal specific splice junctions are due to SNPs at the splice site dinucleotide motifs, because other exonic or intronic SNPs can also affect splicing. However, such differential splicing events could readily be detected by conventional RNA-seq alignment procedures and sQTL detection algorithms (26,71) and are not the focus of this work.

We identified 506 personal specific splice junctions in a RNA-seq data set of 75 European individuals, among which 437 were novel splice junctions not documented in current human transcript annotations (Ensembl version #75). 94 splice junctions had splice site SNPs associated with GWAS signals of human traits and diseases. These involve genes whose splicing variations have been implicated in diseases (such as OA SI, Figure 3A), as well as novel associations between alternative splicing and disease (such as IC A I, Figure 4). To put these numbers in a proper context, as a comparison our previous analysis of alternative splicing in 41 European individuals identified 140 splicing QTLs from the RNA-seq data, including 10 linked to GWAS SNPs (26).

Thus, this personal genome approach to RNA-seq read alignment allows us to tap into a large but previously unknown catalog of splicing variations in human populations, and should be recommended as a routine step for secondary analyses of RNA-seq data with matching genome information. Given that parallel sequencing of DNA and RNA has become a popular strategy for genomic studies of diseases, this approach may also be useful for discovering splicing variations in diseased tissues with RNA-seq data matched with exome sequencing or genome sequencing data. For example, this approach may help identify novel cancer-specific splicing variations arising from somatic mutations that create splice site dinucleotide motifs in cancer genomes. It is also possible to extend the rPGA pipeline to identify personal specific splice junctions arising from other types of genomic variants, such as indels or polymorphic structural variations.

SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.

FUNDING
National Institutes of Health [R01GM088342, R01GM105431, R01NS076631, U01HG007912 to Y.X.]. Y.X. is supported by an Alfred Sloan Research Fellowship. S.S. was a UCLA Amgen Scholar. Funding for open access charge: NIH [U01HG007912]. Conflict of interest statement. None declared.

REFERENCES
1. Nilsen,T.W. and Graveley,B.R. (2010) Expansion of the eukaryotic proteome by alternative splicing. Nature, 463, 457–463.
2. Wang,E.T., Sandberg,R., Luo,S., Khrebtukova,I., Zhang,L., Mayr,C., Kingsmore,S.F., Schroth,G.P. and Burge,C.B. (2008) Alternative isoform regulation in human tissue transcriptomes. Nature, 456, 470–476.
3. Pan,Q., Shai,O., Lee,L.-F., Frey,B.J. and Blencowe,B.J. (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet., 40, 1413–1415.
4. Wang,G.S. and Cooper,T.A. (2007) Splicing in disease: disruption of the splicing code and the decoding machinery. Nat. Rev. Genet., 8, 749–761.
5. Teraoka,S.N., Telatar,M., Becker-Catania,S., Liang,T., Onengut,G., Tolum,A., Chessa,L., Sanal,O., Bernatowska,E., Gatt,R.A. et al. (1999) Splicing defects in the ataxia-telangiectasia gene. ATM: underlying mutations and consequences. Am. J. Hum. Genet., 64, 1617–1631.
6. Ars,E., Serra,E., Garcia,J., Kruyer,H., Gaona,A., Lazaro,C. and Estvill,X. (2000) Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum. Mol. Genet., 9, 237–247.
7. Hull,J., Campino,S., Rowlands,K., Chan,M.S., Copley,T.R., Taylor,M.S., Rockett,K., Elvidge,G., Keating,B., Knight,J. et al. (2007) Identification of common genetic variation that modulates alternative splicing. PLoS Genet., 3, e99.
8. Kwan,T., Benovoy,D., Dias,C., Gurd,S., Provencher,C., Beaulieu,P., Hudson,T.J., Sladek,R. and Majewski,J. (2008) Genome-wide analysis of transcript isoform variation in humans. Nat. Genet., 40, 225–231.
9. Kwan,T., Benovoy,D., Dias,C., Gurd,S., Serre,D., Zuzan,H., Clark,T.A., Schweitzer,A., Staples,M.K., Wang,H. et al. (2007) Heritability of alternative splicing in the human genome. Genome Res., 17, 1210–1218.
10. Coulombe-Huntington,J., Lam,K.C., Dias,C. and Majewski,J. (2009) Fine-scale variation and genetic determinants of alternative splicing across individuals. PLoS Genet., 5, e1000766.
11. Garcia-Blanco,M.A., Baranik,A.P. and Lasda,E.L. (2004) Alternative splicing in disease and therapy. Nat. Biotechnol., 22, 535–546.
12. Ward,A.J. and Cooper,T.A. (2010) The pathobiology of splicing. J. Pathol., 220, 152–163.
13. Lu,Z.X., Jiang,P. and Xing,Y. (2012) Genetic variation of pre-mRNA alternative splicing in human populations. Wiley Interdiscip. Rev. RNA, 3, 581–592.
14. Wang,Z. and Burge,C.B. (2008) Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. Interdiscip. Rev. RNA, 3, 581–592.
15. Sheth,N., Roca,X., Hasting,M.L., Roeder,T., Krainer,A.R. and Sachidanandam,R. (2006) Comprehensive splice-site analysis using large-scale genome sequencing data. Nat. Genet., 38, 535–546.
16. Kurmangaliyev,Y.Z., Sutormin,R.A., Naumenko,S.A., Bazykin,G.A. and Gelfand,M.S. (2013) Functional implications of splicing polymorphisms in the human genome. Hum. Mol. Genet., 22, 3449–3459.
17. Krawczak,M., Reiss,J. and Cooper,D.N. (1992) The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum. Genet., 90, 41–54.
18. Katz,Y., Wang,E.T., Airoldi,E.M. and Burge,C.B. (2010) Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nat. Methods, 7, 1009–1015.
19. Mortazavi,A., Williams,B.A., McCue,K., Schaeffer,L. and Wold,B. (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods, 5, 621–628.
20. Shen,S., Park,J.W., Huang,J., Dittmar,K.A., Lu,Z.X., Zhou,Q., Carstens,R.P. and Xing,Y. (2012) MATS: a Bayesian framework for flexible detection of differential alternative splicing from RNA-Seq data. Nucleic Acids Res., 40, e61.
21. Shen,S., Park,J.W., Lu,Z.X., Lin,L., Henry,M.D., Wu,Y.N., Zhou,Q. and Xing,Y. (2014) rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc. Natl. Acad. Sci. U.S.A., 111, E5593–E5601.
22. Gutierrez-Arcelus, M., Oneng, H., Lappalainen, T., Montgomery, S.B., Buil, A., Yurovsky, A., Bryois, J., Padiouleau, L., Romano, L., Planchn, A. et al. (2015) Tissue-specific effects of genetic and epigenetic variation on gene regulation and splicing. PLoS Genet., 11, e1004958.

23. Lappalainen, T., Summeth, M., Friedlander, M.R., t Hoen, P.A., Monlong, J., Rivas, M.A., Gonzalez-Porta, M., Kurbatova, N., Griebel, T., Ferreira, P.G. et al. (2013) Transcriptome and genome sequencing uncovers functional variation in humans. Nature, 501, 506–511.

24. Lalonde, E., Ha, K.C., Wang, Z., Benmo, A., Kleinman, C.L., Kwan, T., Pastinen, T. and Majewski, J.I. (2011) RNA sequencing reveals the role of splicing polymorphisms in regulating human gene expression. Genome Res., 21, 545–554.

25. Mele, M., Ferreira, P.G., Reverter, F., DeLuca, D.S., Monlong, J., Summeth, M., Young, T.R., Goldmann, D., Pervouchine, D.D., Sullivan, T.J. et al. (2015) Human genomics. The human transcriptome across tissues and individuals. Science, 346, 660–665.

26. Zhao, K., Lu, Z.X., Park, J.W., Zhou, Q. and Xing, Y. (2013) GLMMPS: robust statistical model for regulatory variation of alternative splicing using RNA-seq data. Genome Biol., 14, R74.

27. Pickrell, J.K., Marioni, J.C., Pab, A.A., Degner, J.F., Engelhardt, B.E., Nkadori, E., Veyrieras, J.B., Stephens, M., Gilad, Y. and Pritchard, J.K. (2010) Understanding mechanisms underlying human gene expression variation with RNA sequencing. Nature, 464, 768–772.

28. Battle, A., Mostafavi, S., Zhu, X., Potash, J.L., Wei, T., X., Zhou, Q., van de Geijn, B., McVicker, G., Gilad, Y. and Pritchard, J.K. (2015) Four Promoters of IRF5 Respond Distinctly to Stimuli and Are Affected by Autoimmune-Risk Polymorphisms. Front. Immunol., 4, 360.

29. Tan,J.M., Xiang, P., Cai, J.J. and Xing, Y. (2011) Context-dependent robustness to 5′ splice site polymorphisms in human populations. Hum. Mol. Genet., 20, 1084–1096.

30. Konta, T., Takasaki, K., Ichikawa, K., Emi, M., Toriyama, S., Satoh, H., Ikeda, A., Suzuki, K., Masuda, M., Shibata, Y. et al. (2010) The novel and independent association between single-point SNP of NPH4 gene and renal function in non-diabetic Japanese population: the Takahata study. J. Hum. Genet., 55, 791–795.

31. van de Geijn, B., McVicker, G., Gilad, Y. and Pritchard, J.K. (2015) Tissue-specific effects of autoimmune-risk promoter polymorphisms on expression, exon choice, and translational efficiency of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat. Genet., 38, 550–555.

32. Clark, D.N., Lambert, J.P., Till, R.E., Argueglia, L.B., Greenhalgh, K.E., Henrie, B., Bills, T., Hawley, T.F., Roznik, M.G., Sloan, J.M. et al. (2014) Molecular effects of autoimmune-risk promoter polymorphisms on expression, exon choice, and translational efficiency of interferon regulatory factor 5. J. Interferon Cytokine Res., 34, 354–365.

33. Dieguez-Gonzalez, R., Calaza, M., Perez-Pampin, E., de la Serna, A.R., Fernandez-Gutierrez, B., Castaeneda, S., Largo, R., Joven, B., Narvaez, J., Navarro, F. et al. (2008) Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. Arthritis Rheum., 58, 1264–1274.

34. Kristjansdottir, G., Sandling, J.K., Bonetti, A., Roos, I.M., Milani, L., Wang, C., Gustafsdottir, S.M., Sigurdsdottir, S., Lundmark, A., Tenior, P.J. et al. (2008) Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J. Med. Genet., 45, 362–369.

35. Hiller, M., Huse, K., Szafranski, K., Jahn, N., Hampe, J., Schreiber, S., Backofen, R. and Plater, M. (2006) Single-nucleotide polymorphisms in NAGNAG acceptors are highly predictive for variations of alternative splicing. Am. J. Hum. Genet., 78, 291–302.

36. Tan, W., Basu, S., Kong, X., Pankow, J.S., Aleksic, N., Tan, A., Cushman, M., Boerwinkle, E. and Folsom, A.R. (2010) Genome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study. Blood, 116, 5032–5036.

37. Chakrabarti, A., Jha, B.K. and Silverman, R.H. (2011) New insights into the role of RNase L in innate immunity. J. Interferon Cytokine Res., 31, 49–57.

38. Bonnevie-Nielsen, V., Danish, J.L., Lu, S.Z., Zheng, D.J., Li, M., Martensen, P.M., Nielsen, T.B., Beck-Nielsen, H., Luy, Y.L. and Pociot, F. (2005) Variations in antiviral 2′,5′-oligoadenylate synthetase (2′,5′AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am. J. Hum. Genet., 76, 623–633.

39. Oppermann, U.C. and Maser, E. (2000) Molecular and structural aspects of xenobiotic cytochrome metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase 1 reactions. Toxicology, 144, 71–81.

40. Oppermann, U., Filling, C., Hultz, M., Shafqat, N., Wu, X., Lindh, M., Shafqat, J., Nording, E., Kallberg, Y., Persson, B. et al. (2003) Short-chain dehydrogenases/reductases (SDR): the 2002 update. Chem. Biol. Interact., 143–144, 247–253.

41. Nobel, S., Abrahamson, L. and Oppermann, U. (2001) Metabolic conversion as a pre-receptor control mechanism for lipophilic hormones. Eur. J. Biochem., 268, 4113–4125.

42. Oppermann, U.C., Filling, C. and Jornvall, H. (2001) Forms and functions of human SDR enzymes. Chem. Biol. Interact., 130–132, 699–705.

43. Ioanid, J.P., Thomas, G. and Daly, M.J. (2009) Validating, augmenting and refining genome-wide association signals. Nat. Rev. Genet., 10, 318–329.
59. Schaub, M.A., Boyle, A.P., Kundaje, A., Batzoglou, S. and Snyder, M. (2012) Linking disease associations with regulatory information in the human genome. *Genome Res.*, 22, 1748–1759.

60. Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, L., Junkins, H., Klemm, A., Flicek, P., Manolio, T., Hindorff, L. et al. (2014) The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res.*, 42, D1001–D1006.

61. Buffa, L., Fuchs, E., Pietropaolo, M., Barr, F. and Solimena, M. (2008) ICA69 is a novel Rab2 effector regulating ER-Golgi trafficking in insulinoma cells. *Eur. J. Cell Biol.*, 87, 197–209.

62. Friday, R.P., Pietropaolo, S.L., Profozich, J., Trucco, M. and Pietropaolo, M. (2003) Alternative core promoters regulate tissue-specific transcription from the autoimmune diabetes-related ICA1 (ICA69) gene locus. *J. Biol. Chem.*, 278, 853–863.

63. Martin, S., Kardorf, J., Schulte, B., Lampeter, E.F., Gries, F.A., Melchers, I., Wagner, R., Bertrams, J., Roep, B.O. and Pfützner, A. (1995) Autoantibodies to the islet antigen ICA69 occur in IDDM and in rheumatoid arthritis. *Diabetologia*, 38, 351–355.

64. Winer, S., Astsaturov, I., Cheung, R., Tsui, H., Song, A., Gaedigk, R., Winer, D., Sampson, A., McKerlie, C., Bookman, A. et al. (2002) Primary Sjögren’s syndrome and deficiency of ICA69. *Lancet*, 360, 1063–1069.

65. Tarricone, C., Xiao, B., Justin, N., Walker, P.A., Rittinger, K., Cherfils, J. (2001) Structural mimicry of DH domains by Arfaptin nucleotide exchange factors. *Nat. Cell Biol.*, 2, 68–63.

66. Cherfils, J. (2001) Structural mimicry of DH domains by Arfaptin. *Nature*, 411, 290–294.

67. Martin, J.E., Assassi, S., Día-Gallo, L.M., Simeon, C.P., Castellvi, I., Vicente-Rabaneda, E., Fonollosa, V., Ortego-Centeno, N., Gonzalez-Gay, M.A. et al. (2013) A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. *Hum. Mol. Genet.*, 22, 4021–4029.

68. Damgaard, C.K., Kahn, S., Lykke-Andersen, S., Nielsen, A.L., Jensen, T.H. and Kjems, J. (2008) A S′ splice site enhances the recruitment of basal transcription initiation factors in vivo. *Mol. Cell.*, 29, 271–278.

69. Bieberstein, N.I., Carrillo Oesterreich, F., Straube, K. and Neugebauer, K.M. (2012) First exon length controls active chromatin signatures and transcription. *Cell Rep.*, 2, 62–68.

70. Almada, A.E., Wu, X., Kriz, A.J., Burge, C.B. and Sharp, P.A. (2013) Promoter directionality is controlled by U1 snRNP and polyadenylation signals. *Nature*, 499, 360–363.

71. Moglund, J., Calvo, M., Ferreira, P.G. and Guigo, R. (2014) Identification of genetic variants associated with alternative splicing using sQTLseeker. *Nat. Commun.*, 5, 4698.

72. Samani, N.J., Erdmann, J., Hall, A.S., Hengstenberg, C., Mangino, M., Mayer, B., Dixon, R.J., Meitinger, T., Braund, P., Wichmann, H.E. et al. (2007) Genomewide association analysis of coronary artery disease. *N. Engl. J. Med.*, 357, 443–453.

73. Wellcome Trust Case Control, C. (2007) Genomewide-association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature*, 447, 661–678.

74. Wright, F.A., Strug, L.J., Doshi, V.K., Commander, C.W., Blackman, S.M., Sun, L., Berthiaume, Y., Cutler, D., Cojocaru, A., Collaco, J.M. et al. (2011) Genomewide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. *Nat. Genet.*, 43, 539–546.

75. Painter, J.N., Anderson, C.A., Nyholt, D.R., Macgregor, S., Lin, J., Lee, S.H., Lambert, A., Zhao, Z.Z., Roseman, F., Guo, Q. et al. (2011) Genomewide association study identifies a locus at 7p15.2 associated with endometriosis. *Nat. Genet.*, 43, 51–54.

76. Fellay, J., Shianna, K.V., Ge, D., Colombo, S., Ledegerber, B., Weale, M., Zhang, K., Gumbs, C., Castagna, A., Cossarizza, A. et al. (2007) A whole-genome association study of major determinants for host control of HIV-1. *Science*, 317, 944–947.

77. Verderio, P., Pizzamiglio, S., Southey, M.C., Spurde, A.B., Hopper, J.L., Chen, X., Beesley, J. and Australian Ovarian Cancer Study Group, K.Australian Ovarian Cancer Study Group, K., Schmutzler, R.K., Engel, C. et al. (2010) A BRCA1 promoter variant (rs11655505) and breast cancer risk. *J. Med. Genet.*, 47, 268–270.

78. Wain, L.V., Verwoert, G.C., O’Reilly, P.F., Shi, G., Johnson, T., Johnson, A.D., Bochud, M., Rice, K.M., Henneman, P., Smith, A.V. et al. (2011) Genomewide-association study identifies six new loci influencing pulse pressure and mean arterial pressure. *Nat. Genet.*, 43, 1005–1011.

79. Wijmman, E.M., Pankratz, N.D., Choi, Y., Rothstein, J.H., Faber, K.M., Cheng, R., Lee, J.H., Bird, T.D., Bennett, D.A., Diaz-Arrastia, R. et al. (2011) Genomewide association of familial late-onset Alzheimer’s disease replicates BIN1 and CLU and nominates CUGBP2 in controls. *PLoS Genet.*, 7, e1001308.

80. Cusanovich, D.A., Billstrand, C., Zhou, X., Chavarria, C., De Leon, S., Li, P. et al. (2007) Genome-wide association study of lymphocyte interaction with APOE. *Nat. Commun.*, 5, 4698.

81. Samani, N.J., Erdmann, J., Hall, A.S., Hengstenberg, C., Mangino, M., Mayer, B., Dixon, R.J., Meitinger, T., Braund, P., Wichmann, H.E. et al. (2007) Genomewide association analysis of coronary artery disease. *N. Engl. J. Med.*, 357, 143–153.